These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9688104)

  • 1. The fen-phen finale: a study of weight loss and valvular heart disease.
    Wadden TA; Berkowitz RI; Silvestry F; Vogt RA; St John Sutton MG; Stunkard AJ; Foster GD; Aber JL
    Obes Res; 1998 Jul; 6(4):278-84. PubMed ID: 9688104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
    Burger AJ; Sherman HB; Charlamb MJ; Kim J; Asinas LA; Flickner SR; Blackburn GL
    J Am Coll Cardiol; 1999 Oct; 34(4):1153-8. PubMed ID: 10520805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The longitudinal effects of fenfluramine-phentermine use.
    Fleming RM; Boyd LB
    Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
    Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
    Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After fen-phen.
    Cowley G; Springen K
    Newsweek; 1997 Sep; 130(13):46-8. PubMed ID: 10173270
    [No Abstract]   [Full Text] [Related]  

  • 9. Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't.
    Schiller NB
    J Am Coll Cardiol; 1999 Oct; 34(4):1159-62. PubMed ID: 10520806
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
    JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valvular heart disease with the use of fenfluramine-phentermine.
    Surapaneni P; Vinales KL; Najib MQ; Chaliki HP
    Tex Heart Inst J; 2011; 38(5):581-3. PubMed ID: 22163141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography.
    Vagelos R; Jacobs M; Popp RL; Liang D
    J Am Soc Echocardiogr; 2002 Jun; 15(6):653-7. PubMed ID: 12050608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
    Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
    Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.
    Griffen L; Anchors M
    Arch Intern Med; 1998 Jan; 158(1):102. PubMed ID: 9437392
    [No Abstract]   [Full Text] [Related]  

  • 15. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
    Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
    Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fen-phen and risk of valvular disease.
    SoRelle R
    Circulation; 1997 Sep; 96(6):1705-6. PubMed ID: 9323046
    [No Abstract]   [Full Text] [Related]  

  • 19. Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
    Wadden TA; Silvestry FE; Aber JL; Berkowitz RI; Foster GD; Sutton MG
    Obes Res; 1999 May; 7(3):309-10. PubMed ID: 10348504
    [No Abstract]   [Full Text] [Related]  

  • 20. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.